Pathway Genomics had a busy week. The San Diego, CA-based genetic testing laboratory began by securing an investment from IBM that will also give it access to Watson, before going on to form a cancer research collaboration with a registry created by researchers from Memorial Sloan Kettering, Mayo Clinic, Dana-Farber and other organizations.
AstraZeneca has detailed the data from two of three studies of its late-stage combination program for lesinurad, a new drug for gout obtained in their $1.26 billion buyout of Ardea, which showed that the treatment hit the desired biomarker for blood levels of uric acid as promised--but added today that it failed to actually reduce the rate of painful flare-ups of the disease for patients in the study.
Bristol-Myers Squibb has pulled the covers off of impressive Phase III data on Opdivo (nivolumab), pointing to a 73% survival rate among advanced melanoma patients after one year of therapy compared to 42% for the long-used chemo drug dacarbazine.
Pet-drug developer Kindred Biosciences announced Thursday that its net loss in the third quarter was $6.1 million, up from $1.2 million in the same period a year ago, as research and development expenses grew to $3.8 million from $1 million.
Simply wishing away pain is not as far-fetched as you probably think, research from Swiss scientists shows. Using electroencephalography they were able to harness thought-specific brain waves to convert genes into proteins, or what's known as gene expression.
Boehringer Ingelheim is working with managed care giant WellPoint in an effort to use real-world data to inform the development of new treatments of atrial fibrillation, keeping up with a sweeping trend in cardiovascular R&D.
Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.
The U.K. government has set out its vision for how the National Health Service will transform into a tech-savvy, research-enabling organization by 2020. As part of the wide-reaching strategy, NHS England will create "test bed" sites at which bioinformatics approaches and other tools will be tested.
J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.
Over the past few decades, the harsh realities of complex biology have brought back to Earth some pie-in-the-sky projections about the value of genomics in biotech R&D. But the industry still devotes the vast majority of research spending to target-based drug development, an imbalance that could be a factor in Big Pharma's slumping efficiency rates.